|
Echinacea
|
DB14240 |
|
|
FLX475
|
DB15570 |
[FLX475 is a small molecule CCR4 antagonist being investigated for the treatment of cancer.[L9875]] |
|
alpha-Pinene
|
DB15573 |
|
|
Honey
|
DB14242 |
[Honey is an animal extract used in some OTC (over-the-counter) products. It is not an approved drug.] |
|
CTX001
|
DB15572 |
[CTX001 is being developed by CRISPR Therapeutics and Vertex. It is an autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells in clinical trials for the treatment of severe sickle cell disease and severe beta-thalassemia.[L10139]] |
|
Caviar, unspecified
|
DB14241 |
[Caviar, unspecified is an animal extract used in some OTC (over-the-counter) products. It is not an approved drug.] |
|
4-(Acetylamino)-3-Amino Benzoic Acid
|
DB02268 |
|
|
[4-({[5-Benzyloxy-1-(3-Carbamimidoyl-Benzyl)-1h-Indole-2-Carbonyl]-Amino}-Methyl)-Phenyl]-Trimethyl-Ammonium
|
DB02269 |
|
|
gamma-Glutamyl[S-(2-iodobenzyl)cysteinyl]glycine
|
DB03597 |
|
|
Flufenamic acid
|
DB02266 |
[An anthranilic acid derivative with analgesic, anti-inflammatory, and antipyretic properties. It is used in musculoskeletal and joint disorders and administered by mouth and topically. (From Martindale, The Extra Pharmacopoeia, 30th ed, p16)] |
|
Argininosuccinate
|
DB02267 |
|
|
Al-6629, [2h-Thieno[3,2-E]-1,2-Thiazine-6-Sulfonamide,2-(3-Methoxyphenyl)-3-(4-Morpholinyl)-, 1,1-Dioxide]
|
DB03598 |
|
|
CRA_9785
|
DB03595 |
|
|
O2-Sulfo-Glucuronic Acid
|
DB02264 |
|
|
N-[2-(1h-Indol-5-Yl)-Butyl]-4-Sulfamoyl-Benzamide
|
DB03596 |
|
|
Ethyl-Trimethyl-Silane
|
DB02265 |
|
|
Phenserine
|
DB04892 |
[Phenserine is under development by Axonyx, a US biopharmaceutical company that focuses on treatments for dementia. Phenserine is a next generation acetylcholinesterase (AChE) inhibitor indicated for the treatment of AD. Unlike currently marketed AChE inhibitors, it has a dual mechanism of action that also includes anti-amyloid activity, which may confer disease-modifying effects in patients with AD. If this is substantiated in an ongoing clinical trial then phenserine may open the door to an entirely new type of treatment for AD. Axonyx announced on 20 September 2005 that phenserine was ineffective in two curtailed phase 3 trials.] |
|
P-Hydroxybenzaldehyde
|
DB03560 |
|
|
Immucillin-G
|
DB02230 |
|
|
Becocalcidiol
|
DB04891 |
[Becocalcidiol is a vitamin D(3) analogue which has not caused hypercalcaemia or significant irritation in preclinical trials.] |
